Abiopharma

Vistagen Appoints Nick Tressler as Chief Financial Officer

The Oncology Institute Announces Resignation of Board Member Gabe Ling

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants

Philips expands commercial availability of world’s first real-time AI-enabled light-based 3D navigation solution for image-guided therapy

Mirum Pharma - Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease